Bio-Tissue, Inc. Highlights Publication of DREAM Study

MIAMI--()--Bio-Tissue, Inc., a TissueTech, Inc. company, highlighted the publication of the DRy Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.*

This retrospective study was conducted at 10 clinical sites in the United States, led by Dr. Marguerite McDonald and Dr. Hosam Sheha. It demonstrates that a single application of self-retained cryopreserved amniotic membrane (cAM) (PROKERA® Biotissue, Miami FL) can accelerate the recovery of corneal surface and help reduce signs and symptoms of DED for an extended period of at least three months. These results are consistent with another prospective study that showed that this lasting effect is correlated with corneal nerve regeneration as evidenced by an increase in corneal nerve density and improved corneal sensitivity.**

“The clinical evidence presented in DREAM continues to further establish the effectiveness of cryopreserved amniotic membrane in supporting healing in patients, and our commitment to provide tissue products that address the entire ocular surface disease spectrum,” said Adrian Roji, Chief Commercial Officer of TissueTech. “Our cryopreserved amniotic tissue supports the healing of the ocular surface, and is also promising with respect to corneal nerve integrity.”

Bio-Tissue, a subsidiary of TissueTech, is the leader in biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue serves an unmet need providing better surgical and therapeutic alternatives for eye care professionals to support the healing of ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis pterygium and dry eye.

Bio-Tissue utilizes its proprietary CryoTek® process, a cryopreservation technology, to preserve the biological and structural integrity of the natural tissue. Published studies have demonstrated that the CryoTek process provides an allograft that is essentially equivalent to fresh tissue.

* McDonald M, Sheha H, Tighe S, et al. Treatment Outcomes in the DRy Eye Amniotic Membrane (DREAM) Study. Clinical Ophthalmology 2018: 12, 677-81.

**John T, Tighe S, Sheha H, et al. Rock, “Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease” The Journal of Ophthalmology, August 2017

About Bio-Tissue, Inc.

Bio-Tissue (, a business unit of TissueTech, Inc., develops and markets tissue that allow eye care professionals to utilize and advance the standard of care for treating the ocular surface. Its core products include cryopreserved amniotic membrane and umbilical cord-based tissue. The company’s proprietary CryoTek preservation method ensures the tissue retains its biologic activity.

About TissueTech, Inc.

TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue®, Inc., pioneered the development and clinical application of amniotic tissue-based products. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing.


Bio-Tissue, Inc.
Chris Gale, 646-695-2883

Release Summary

Bio-Tissue, a TissueTech company, highlighted the publication of the DRy Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.



Bio-Tissue, Inc.
Chris Gale, 646-695-2883